The Cancer Dashboard for Central and Southeastern Europe Central European Cooperative Oncology Group (CECOG) Christoph C. Zielinski, President
Scientific achievements in cancer research » » Improved understanding of Development of sophisticated the biology of different treatment strategies cancers » treatment based on » risk factors individual genetic profile » underlying molecular » Improved diagnosis and mechanisms treatment » » earlier detection Advances in diagnostic procedures » increased rates of cure » genetic profiling » extension of lives » biomarker testing » improved quality of live » earlier detection
CEE: Cancer-Related Issues - to be ameliorated and discussed I. cancer incidence rates • » risk factors associated with emergence of certain cancer types • primary prevention patient care • allocated technological and human resources • availability, access to and reimbursement of • molecular testing
CEE: Cancer-Related Issues - to be ameliorated and discussed II. Poor survival and high cancer-driven mortality • » more deadly cancer types » screening programs » diagnosis at later stages associated with poorer outcome » fewer available treatment options » limitations in access to treatment » delays in treatment initiation » variations in lower and/delayed availability of novel treatments
GOIA: Discussions, Plans and Aims for CEE I. » Implementation of Population-based cancer registries » National prevention programs » information regarding treatment » tobacco smoking » “clinical benefit ” and “value” of » obesity treatment modalities » vaccinations (HBV and HPV) » effectiveness, toxicity, and cost of » alcohol consumption cancer medicines » Population-based screening programs » Breast cancer » Cervical cancer » Colorectal cancer » Prostate cancer » National cancer control plans
GOIA: Discussions, Plans and Aims for CEE II. » » Reimbursement of new Approval of new medicines by FDA and EMA medicines » Implementation of the ESMO- » decisions more rapid Magnitude of Clinical Benefit » inclusion of novel drugs in Scale into the approval routine clinical practice process (FDA, EMA) which are based on “value” rather than » better access to clinicial trials statistical significance » additional investments in cancer care » more organized, value- oriented application of novel diagnostic and treatment approaches
GOIA: Discussions, Plans and Aims for CEE III. Appreciation of patient advocacy groups as important stakeholders » educated regarding cancer research » involved in clinical trials development on a regional level » increasing access to clinical trials » involved in approval processes » decision-making with regard to prioritise cancer treatment reimbursement
GOIA: Discussions, Plans and Aims for CEE IV. Development of a “ cancer patient pathway ” » recording and documenting treatment outcomes » joint endeavour of healthcare professionals and patient advocacy groups » Goal: implementation of national systems of comprehensive cancer care from primary prevention to palliative care Analysis of patient paths by patient advocacy groups Social education » attitude towards cancer » advocate that cancer is to a large part a preventable chronic disease
A Cancer Dashboard for CEE Monitoring Key Metrics allow to effectively scrutinize cancer care performance • to identify ways to improve cancer services • to use local data to make change happen • The Cancer Dashboard is designed to help review cancer care in CEE countries to assess and improve the quality of services.
Prevention Educational initiatives, General Initiatives awareness/prevention programs for » Legislation/regulations which restrict cancer risk factors access and exposure to harmful products and environments » tobacco smoking » Educational campaigns tailored to different » obesity audiences to raise awareness on different » vaccinations (HBV and HPV) risk factors for cancer » alcohol consumption » Dissemination of the European Code against Cancer (IARC) in schools, workplaces, health and community centers » Celebration and appreciation of events which give visibility to cancer prevention » Introduction of explicit funding and support for cancer epidemiology, Public Health research in the field of prevention
Prevention: Key Performance Indicators » Number of educational » Number of patients diagnosed with initiatives/awareness genital warts programs/sustainable prevention » Number of women newly diagnosed initiatives with cervical cancer » Changes in legislation (smoke-free » Number of patients diagnosed with public areas, advertising for high- oropharyngeal, penile, anus, cancers calorie beverages/alcohol, » Number of patients diagnosed with vaccination programs) HBV/liver disease due to HBV » Smoking rates in adults/selected high » Number Diagnosed Stage I and II risk groups cancers one year following » Percentage of inhabitants with awareness campaign obesity » Screening Initiatives: Number of new » Number of patients diagnosed with cancer cases with early stage cancer diabetes type II in 2025 – 2030 – 2035
Diagnosis: Key Performance Indicators (KPIs) Initiative improve imaging Initiative Standardizing and diagnostics implementation of molecular testing/characterization of cancer samples in the CEE » Increase regional coverage with state-of-the art medical imaging » tools General reimbursement of molecular testing throughout the entire CEE » Modernization to state-of-art region equipment » KPI: Percentage of patients with » Increasing the number of qualified molecular testing results manpower » KPI: Percentage of patients on » KPI: Wait time for diagnostic individualized therapy imaging (CT scan, MRI, bone scan)
Systemic Treatment and Radiotherapy: Key Performance Indicators Initiative: increase radiotherapy in Initiative: Access to novel the treatment of patients with cancer systemic treatment » Increase number of radiotherapy » Value-oriented reimbursement machines processes for novel diagnostic and » Modernize equipment to state-of-the- treatment art » KPI: Number of affordable new » Increase the number of qualified therapies/care solutions manpower reimbursed in 2025 – 2030 – 2035 » KPI: Wait time for adjuvant radiation therapy from the final pathology report » KPI: Number of people living with cancer for >10 years after diagnosis in 2025 – 2030 – 2035
Treatment: Analyses and Key Performance Indicators I. » Foster analysis of patients’ pathways/journey by patient advocacy groups » Time between diagnosis and initial treatment, with specification of treatment modality » Percentage of patients treated on a clinical trial at any time after diagnosis » Complete synoptic pathology report according to respective national guidelines » Percentage of patients presented to a multidisciplinary tumor board at any time after diagnosis
Treatment: Key Performance Indicators II. Accelerate access to therapy/Improving quality of diagnosis » Percentage of patients with documented evidence of multidisciplinary team recommendations » Percentage of patients with evidence of communication re. the treatment plan to the GP » Overall survival by stage at initial therapy for individual malignant diseases » Percentage of patients with high-grade (3 or 4) acute toxicity with cytotoxic chemotherapy
Thank you!
Recommend
More recommend
